Introduction: Airway mucus gel layer serves as a key delivery barrier that limits the
performance of inhaled drug delivery nanoparticles. Conventional nanoparticles are readily …

Mucoadhesive particles (MAP) have been widely explored for pulmonary drug delivery
because of their perceived benefits in improving particle residence in the lungs. However …

Airway mucus is a complex viscoelastic gel that provides a defensive physical barrier and
shields the airway epithelium by trapping inhaled foreign pathogens and facilitating their …

Mucus is a viscoelastic hydrogel that lubricates and protects mucosal tissues such as the
eyes, lung, gastrointestinal tract, and vagina. Nanoparticle-based drug delivery systems …

Mucus is a viscoelastic and adhesive gel that protects the lung airways, gastrointestinal (GI)
tract, vagina, eye and other mucosal surfaces. Most foreign particulates, including …

Most attempts to achieve sustained drug delivery to pulmonary tissues using nanoparticles
have focused on mucoadhesive particles (MAP). However, MAP become trapped in the …

In mucosal drug delivery, two design goals are desirable: 1) insure drug passage through
the mucosal barrier to the epithelium prior to drug removal from the respective organ via …

The pulmonary route offers an exceptional, non-invasive administration site for drug
delivery. The principal characteristics that make the lungs an appealing route for drug …

Mucus is a complex viscoelastic gel and acts as a barrier covering much of the soft tissue in
the human body. High vascularization and accessibility have motivated drug delivery to …

The mucus barrier is well established as a formidable barrier to exogenous substances and
forms the first line of defense for mucosal surfaces. Drugs and particle systems are known to …